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Abstract: Spray-drying stands as one of the most used techniques to produce inhalable 17 
microparticles, but several parameters from both the process and the used materials, affect the 18 
properties of the resulting microparticles. In this work we describe the production of drug-loaded 19 
chondroitin sulfate microparticles by spray-drying, testing the effect of using different solvents 20 
during the process. Full characterisation of the polymer and of the aerodynamic properties of the 21 
obtained microparticles are provided envisaging an application in inhalable tuberculosis therapy. 22 
The spray-dried microparticles successfully associated two first-line antitubercular drugs (isoniazid 23 
and rifabutin) with satisfactory production yield (up to 85%) and drug association efficiency (60% – 24 
95%). Ethanol and HCl were tested as co-solvents to aid the solubilisation of rifabutin and 25 
microparticles produced with the former generally revealed the best features, presenting a better 26 
ability to sustainably release rifabutin. Moreover, these presented aerodynamic properties 27 
compatible with deep lung deposition, with aerodynamic diameter around 4 μm and fine particle 28 
fraction of approximately 44%. Finally, it was further demonstrated that the antitubercular activity 29 
of the drugs remained unchanged after encapsulation independently of the used solvent.  30 
Keywords: chondroitin sulfate, isoniazid, inhalable microparticles, rifabutin, solvents, spray-drying 31 
 32 
1. Introduction 33 
Polysaccharides have been frequently used as matrix materials of inhalable microparticles aimed 34 
at lung drug delivery and spray-drying is a predominant technique applied in their production. 35 
Natural materials show the general advantage of having higher probability to provide 36 
biocompatibility and biodegradability, rendering them attractive for pharmaceutical applications. 37 
Chondroitin sulfate (ChS) is a natural polymer commonly found on proteoglycans in several tissues, 38 
including the lungs [1]. It is composed of alternating sulfated N-acetylgalactosamine and glucuronic 39 
acid residues, both referred to be recognised by macrophage receptors [2, 3], which provides an 40 
important advantage in macrophage targeting strategies [4]. Tuberculosis is a respiratory disease 41 
characterised by the intracellular accumulation of the infectious agent (Mycobacterium tuberculosis) in 42 
the alveolar macrophages. Direct lung delivery of the antibiotics could, thus, bring advantages over 43 
the conventional oral therapy, as it co-localises drugs and pathogenic agents in the same 44 
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compartment. Inhalable carriers have, however, to be optimised to reach the alveoli, where 45 
macrophages are located.  46 
According to the World Health Organization (WHO), combined therapy of tuberculosis is 47 
mandatory to potentiate the treatment efficiency [5], and isoniazid (INH) and rifabutin (RFB) are two 48 
of the used first-line drugs [6]. They display different characteristics, namely regarding molecular 49 
weight and aqueous affinity. In this regard, INH is a 137 g/mol hydrophilic molecule, while RFB has 50 
847 g/mol and is hydrophobic, thus requiring organic or acidic solvents to dissolve. In parallel, the 51 
literature reports that the use of different solvents in the spray-drying of individual drugs has an 52 
effect on particle size, density, shape and surface appearance. Specifically, it is described that 53 
hydrophilic drugs processed by spray-drying may generate smaller particle sizes if surrounded by 54 
solvents with higher water content [7]. In turn, hydrophobic drugs lead to smaller and more porous 55 
particles when processed in more organic solvents [8]. To our knowledge, the comparison of the effect 56 
of different solvents in a mixture of two drugs of opposite character (one hydrophilic and the other 57 
hydrophobic), in the same formulation is not reported. 58 
Bearing in mind the usefulness of a single formulation of inhalable microparticles conjugating 59 
two antitubercular drugs, following the WHO requirements on tuberculosis therapy, this work 60 
focused on studying the effect of using different co-solvents in the spray-drying process. Specifically, 61 
ethanol and hydrochloric acid (HCl) were tested as co-solvents, along with water, in a spray-drying 62 
process envisaging the production of ChS microparticles loaded with INH and RFB. The molecular 63 
mass distribution was evaluated for ChS and ChS-based microparticles, and a rheological study 64 
performed, in order to determine the effect of spray-drying on the polymer properties. The effect of 65 
the microencapsulation process on the antimicrobial activity of the drugs was also evaluated, 66 
encompassing the effect of using different solvents. Finally, the respirability of the produced dry 67 
powders was characterised to ascertain the effect of the solvents on the aerodynamic properties, and 68 
to establish the potential of the carriers for an inhalable strategy to treat tuberculosis.  69 
2. Materials and Methods  70 
2.1. Materials 71 
ChS was acquired from Creative Biomart (USA). Acetic acid, INH, Tween 80®, phosphate buffer 72 
saline (PBS) tablets pH 7.4, thiazolyl blue tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) 73 
and HCl were purchased from Sigma-Aldrich (Germany). RFB was supplied by Chemos (Germany). 74 
Hydroxypropylmethylcellulose (HPMC) capsules (size 3) were received from Capsugel (Colmar, 75 
France). The RS01 Dry Powder Inhaler was a kind gift from Plastiape S.p.a. (Italy). Middlebrook 7H9 76 
(M7H9) and oleic acid, albumin, dextrose and catalase (OADC) supplement were purchased from 77 
Remel (Lenexa, USA). Ultrapure water (MilliQ, Millipore, UK) was used throughout. All other 78 
chemicals were reagent grade. 79 
2.2. Polymer purification 80 
ChS from Creative Biomart (USA) was not of pharmaceutical grade and contained 5.52% (w/w) 81 
of protein on its composition. A purification of ChS was, thus, performed by ethanol precipitation. 82 
To do so, commercial ChS was solubilised in water at 5% (w/w, 200 mL) and poured over 250 mL of 83 
ethanol. This was left to rest at 4 ºC overnight. After that, the dispersion was centrifuged (22 000 g, 4 84 
ºC, 1 h). The polymer was recollected from the pellet, freeze-dried and stored in a desiccator for 85 
further use. All the experiments described below were performed with purified ChS. 86 
2.3 Microparticle production 87 
ChS microparticles were prepared by spray-drying, either unloaded or containing an association 88 
of the antitubercular drugs INH and RFB. ChS was used at 2% (w/v) in all cases and the drug-loaded 89 
microparticles were produced at ChS/INH/RFB mass ratio of 10/1/0.5. While INH was solubilised in 90 
water, the hydrophobic character of RFB required the use of co-solvents. Ethanol 70% (v/v) and HCl 91 
0.01 M were tested for this end and the obtained RFB solution was then added to the previously 92 
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formed ChS/INH solution. When ethanol was used, final water/ethanol ratio of 80/20 (v/v) was 93 
applied in the spraying solution, while HCl was used at a final concentration of 0.002 M.  94 
Microparticles were produced from both solutions using a laboratory mini spray-dryer (Büchi 95 
B-290, Büchi Labortechnik AG, Switzerland) operating in open mode and equipped with a high-96 
performance cyclone. The operating parameters were: inlet temperature: 175 ± 2 ºC, aspirator setting: 97 
90%, feed rate: 0.7 ± 0.1 mL/min, and spray flow rate: 473 L/h. These conditions resulted in outlet 98 
temperature of 110 ± 2 ºC. After spray-drying, microparticles were collected, placed in a dark flask 99 
and stored inside a desiccator until further use.  100 
The spray-drying yield was calculated by gravimetry, comparing the total amount of solids 101 
initially added with the resultant weight of collected microspheres. 102 
2.4. Characterisation of ChS-based microparticles 103 
The morphology of microparticles was characterised by field emission scanning electron 104 
microscopy (FESEM; FESEM Ultra Plus, Zeiss, Germany). Dry powders were placed onto metal plates 105 
and 5 nm thick iridium film was sputter-coated (model Q150T S/E/ES, Quorum Technologies, UK) 106 
on the samples before viewing.  107 
Microparticle size was estimated as the Feret’s diameter and was directly determined by optical 108 
microscopy (Microscope TR 500, VWR international, Belgium) from the manual measurement of 300 109 
microparticles (n = 3). 110 
The particle size distribution was determined by laser light scattering (Spraytec, Malvern 111 
Panalytical, UK). To do so, approximately 15 mg of dry powder were dispersed in 15 mL of 2-112 
propanol and sonicated for 5 min. The volume-based size distribution was characterised and the 113 
particle sizes below which 10%, 50% and 90% of the spray lies determined, being expressed as Dv(10), 114 
Dv(50) and Dv(90). From these values, span was calculated as follows: 115 
Span = 
𝐷𝑣(90)−𝐷𝑣(10)
𝐷𝑣(50)
 (1) 
The analyses were carried out in triplicate with an obscuration threshold of 10%. 116 
Tap density (g/cm3) was determined using a tap density tester (Densipro 250410, Deyman, 117 
Spain), by measuring the volume of a known weight of powder before and after tapping, respectively 118 
(n = 3). The determination of tap density involved tapping the sample until no further reduction of 119 
powder volume was observed (average of 180 taps).  120 
2.5. Determination of drug association and release  121 
To determine the drug content, drug-loaded microparticles were incubated in 0.1 M acetic acid, 122 
under magnetic stirring for 30 min, thus ensuring complete dissolution of microparticles. After 123 
filtration (0.45 µm), quantification was performed by high performance liquid chromatography 124 
(HPLC, Agilent 1100 series, Germany). A LiChrospher® 100 RP-18 (5 µm) column of 4 mm i.d.×250 125 
mm length with security guard cartridge (CS, Germany) was used. Detection was performed by a 126 
diode array detector at 275 nm. Mobile phase consisted in a mixture of 20 mM phosphate buffer pH 127 
= 4 (A) and acetonitrile (B), flowing at a rate of 1.0 mL/min. Gradient started as 95:5 (A:B) for the first 128 
5 min and changed to 30:70 at 8 min, remaining as such until 14 min. It returned then to initial 129 
conditions at 16 min, for a total run time of 17 min. Under these conditions, retention times of INH 130 
and RFB were 4.0 and 12.0 min, respectively. A linear calibration plot for INH and RFB was obtained 131 
over the range of 10-400 μg/mL (n = 3). Drug association efficiency (AE) and microparticle (MP) 132 
loading capacity (LC) were estimated as follows (n = 3): 133 
AE (%) = (Real amount of drug on MP/ Theoretical amount of drug on MP) x 100, (2) 
LC (%) = (Real amount of drug on MP/Weight of MP) x 100, (3) 
Drug release was determined in PBS pH 7.4 added of 1% (v/v) Tween 80®. The assay respected 134 
sink conditions, with the maximum amount of drug being always below 30% of maximum solubility 135 
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[9]. INH solubility was considered 274.0 ± 4.8 mg/mL [10], while that of RFB was 0.496 mg/mL [11]. 136 
A determined amount of microparticles (30 mg) was incubated with the medium (10 mL), at 37 °C, 137 
under mild shaking (100 rpm, orbital shaker OS 20, Biosan, Latvia). Samples (1 mL) were periodically 138 
collected and the amount of each drug quantified as indicated above (n = 3). Similarity factor (f2) was 139 
used to compare the release profile of the different drugs and formulations (similar profiles present 140 
a f2 value not lower than 50) [12].  141 
2.6. Molecular mass distribution 142 
High performance size exclusion chromatography (HPSEC) was selected to define the molar 143 
mass profile of ChS, both in the form of polymer and microparticles (unloaded). To perform the 144 
analyses, the HPLC equipment (Agilent 1100 series, Germany) was supplied with two columns (300 145 
× 7.8 mm) in series (TSKGel G3000PWXL and TSKGel G2500PWXL, Tosoh Bioscience, Stuttgart, 146 
Germany), along with a PWX-guard column (40 x 6 mm). Samples were filtered (0.45 µm) and 147 
analysed using a refractive index (RI) detector, under the following conditions: 70 °C, Milli-Q water 148 
as mobile phase and flow rate of 0.4 mL/min. Dextrans (DX) with molecular weight ranging from 12 149 
to 80 kg/mol (Fluka, MO, USA) were used as standards. Analyses were performed at least in 150 
duplicate. 151 
2.7. Rheology: Steady-state shear measurements  152 
A rheological study was performed on ChS polymer, unloaded ChS microparticles and 153 
ChS/INH/RFB microparticles prepared with either ethanol or HCl. Aqueous dispersions at 10 g/L 154 
were prepared in all cases, dispersing the corresponding amount of sample in distilled water, under 155 
stirring for 15 min, at room temperature. Steady-shear flow curves in terms of apparent viscosity vs. 156 
shear rate were conducted on a controlled-stress rheometer (MCR 302, Paar Physica, Austria) using 157 
a plate-plate geometry (25 mm diameter, 0.5 mm gap). Flow measurements were obtained by 158 
decreasing and, then, increasing shear rate, following a logarithmic ramp to assess the presence of 159 
hysteresis. All trials were made at 25 ºC and were controlled by a Peltier system (± 0.01). In all cases, 160 
aqueous dispersions were sealed with light paraffin oil to avoid water loss during measurements and 161 
were rested for 10 min in the measurement system to allow sample structural equilibration. All 162 
experiments were performed at least in triplicate. 163 
2.8. Aerodynamic characterisation of microparticles using an Andersen cascade impactor 164 
HPMC size 3 capsules were filled with 30 mg of ChS/INH/RFB dry powder, either prepared with 165 
ethanol or HCl. The content of three capsules was discharged in each aerodynamic test using the 166 
medium resistance RS01® inhaler (Plastiape Spa, Italy). The experiments were performed in triplicate. 167 
The device was connected to the Andersen cascade impactor (ACI, Copley Scientific, UK) which 168 
operates at 60 L/min, ensuring a pressure drop of 4 kPa through the device. This was activated for 4 169 
s in order to let 4 L of air passing through the system, thus complying with the standard procedure 170 
described by USP 38 and Ph.Eur.8 [13, 14].  171 
ACI separates particles according to their aerodynamic diameter and it was assembled using the 172 
appropriate adaptor kit for the 60 L/min air flow test. Cut-offs of the stages (-1 to 6) at the air flow 173 
rates adopted in this work are reported in Table 1. A glass fiber filter (Whatman, Italy) was placed 174 
right below stage 6 to collect particles with diameter lower than that of stage 6 cut-off. 175 
 176 
Table 1. Cut-off aerodynamic diameter (µm) for stages of Anderson cascade impactor (ACI) used at 177 
60 L/min. 178 
 179 
 180 
Stage -1 Stage -0 Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Stage 6 
8.60 6.50 4.40 3.20 1.90 1.20 0.55 0.26 
Polymers 2020, 12, x FOR PEER REVIEW 5 of 13 
 
The plates of the impactor were coated with a thin layer of ethanol containing 1% (w/v) Tween 181 
20® to prevent particle bounce. The drugs were recovered from the apparatus with water/acetonitrile 182 
mixture (50/50, v/v) and quantified by HPLC (Agilent 1200 series, Germany), as described above.  183 
The quantification of drugs deposited inside the impactor enabled the calculation of different 184 
aerodynamic parameters. The emitted dose (ED) is the amount of drug ex-device, considered the total 185 
amount of drug collected in the impactor (induction port, stages -1 to 6 and filter). The metered dose 186 
(MD) is the amount of drug loaded in the capsules, determined by adding all the drug collected in 187 
the impactor and in the inhaler (device, induction port, stages -1 to 6 and filter). The mass median 188 
aerodynamic diameter (MMAD) was determined by plotting the cumulative percentage of mass less 189 
than the stated aerodynamic diameter on probability scale versus aerodynamic diameter on 190 
logarithmic scale. The fine particle dose (FPD) corresponds to the mass of drug particles with 191 
aerodynamic diameter lower than 5 µm calculated using the particle size distribution equation 192 
obtained from the ACI analysis. The fine particle fraction (FPF) is the ratio between FPD and MD. 193 
The recovery (%) is the percentage of MD versus the labelled dose. The recovery ranged within 194 
86-91% in all the experiments, being thus coincident with the requisites of the pharmacopeia [13, 14].  195 
2.9. In vitro determination of antitubercular activity 196 
The in vitro antitubercular efficacy of microparticles was evaluated against Mycobacterium bovis 197 
bacillus Calmette-Guérin (BCG). The Minimum Inhibitory Concentration (MIC) value of free and 198 
microencapsulated INH and RFB was determined by the microdilution method [15]. ChS/INH/RFB 199 
microparticles and the powders of free drugs were exposed to UV light for 10 min to provide 200 
sterilisation. Then, a solution of each dry powder was prepared at 1 mg/mL and diluted to the desired 201 
drug concentrations. First, 1 mg/mL stock solution of INH was prepared by dissolving the drug in 202 
the M7H9 supplemented medium. RFB was previously solubilised in DMSO (1 mg/mL) and then 203 
diluted with M7H9 broth. Drug stock solutions were mixed to reach concentrations corresponding to 204 
drug loadings. Two-fold dilutions of the antibiotics/formulations were performed to obtain final 205 
concentrations of RFB from 0.001 to 0.125 µg/mL and of INH from 0.008 to 1 µg/mL. A 1/10 dilution 206 
of a McFarland 1.0 turbidity standard suspension of M. bovis BCG was inoculated (20 µL of inoculum 207 
in 180 µL of medium or test solution) with a multichannel pipette, delivering approximately 104 CFU 208 
per well. The outside lane of wells (a frame-like) were filled with sterile distilled water to avoid the 209 
evaporation of microplate content. The plates were covered with the lid, sealed with parafilm and 210 
incubated at 37 °C (Binder, USA) for 7 days. Afterwards, 30 μL of MTT sterile solution were added 211 
to each well, followed by 4 h of incubation at 37 °C. Then, 50 μL of DMSO were added into the wells 212 
to solubilise the tetrazolium blue crystals that were produced, which is proportional to the growth 213 
rate of mycobacteria. The absorbance was measured by spectrophotometry (Infinite M200, Tecan, 214 
Austria) at 540 nm. The assays were performed in triplicate. The MIC value was considered the lowest 215 
that inhibited mycobacteria growth by 95 – 100% [16, 17]. 216 
2.10. Statistical analysis  217 
The student t-test and the one-way analysis of variance (ANOVA) with the pairwise multiple 218 
comparison procedures (Holm-Sidak method) were performed to compare two or multiple groups. 219 
All analyses were run using Sigmaplot (version 12.5) and differences were considered to be 220 
significant at a level of p < 0.05. 221 
 222 
3. Results and discussion 223 
3.1. Preparation and characterisation of ChS microparticles 224 
ChS undergone an initial step of purification in order to maximise polymer content and avoid 225 
the presence of proteins. The purified polymer was used to prepare microparticles loaded with a 226 
combination of INH and RFB. As far as we know, this is the first time that ChS is being proposed as 227 
platform for the inhalable therapy of tuberculosis. The microparticles were prepared by spray-drying, 228 
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resulting in yields of approximately 85% (Table 2), which were deemed very satisfactory [18]. INH is 229 
a hydrophilic drug, but RFB has hydrophobic character, thus requiring solvents other than water to 230 
solubilise. Despite spray-drying permits processing a suspension, not requiring the solubilisation of 231 
all components of the spraying dispersion, it was decided to provide the complete solubilisation of 232 
both drugs in order to ensure a higher level of homogeneity in the final product. Ethanol and HCl 233 
were, then, tested as co-solvents of RFB, being mixed with water.  234 
Disregard of the used solvent, the obtained particles generally exhibited a spherical shape, as 235 
observed in Figure 1. Moreover, the association of the drugs translated into the production of more 236 
wrinkled and corrugated microparticles (Figures 1B and 1C) comparing with the unloaded 237 
counterparts (Figure 1A). Objectively, the use of different solvents had no effect on microparticle 238 
morphology. The literature reports already several formulations of ChS microparticles, although 239 
none used spray-drying and different co-excipients were included in all cases. Nevertheless, it was 240 
interesting to notice that the spherical shapes and smooth surfaces observed in the unloaded 241 
microparticles reported herein, were common characteristics [19-21]. The microphotographs suggest 242 
that the size of drug-loaded particles tends do decrease upon drug association, having a higher 243 
number of small particles comparing with unloaded particles. Comparing de Dv50 of the produced 244 
microparticles, a significant decrease from 9.6 μm of the unloaded particles to 4.1 μm of the drug-245 
loaded counterparts was observed (p < 0.05, Table 2). This size range is reported as adequate to 246 
potentiate phagocytosis by macrophages [22], which could be advantageous in the treatment of 247 
intracellular diseases or vaccination approaches [23, 24]. 248 
 249 
 250 
Figure 1. Microphotographs of unloaded ChS microparticles (A) and ChS/INH/RFB microparticles 251 
produced with water-ethanol (B) and water-HCl (C) as solvents, as obtained by scanning electron 252 
microscopy. Scale bar is 10 µm. 253 
The tap density was determined to be around 0.5 – 0.6 g/cm3 for the dry powders corresponding 254 
to unloaded microparticles and microparticles produced with HCl, decreasing to 0.3 g/cm3 for 255 
microparticles produced with ethanol. A lower density has been correlated with less cohesive 256 
powders and better flowability [25], comprising an obvious advantage. INH was associated to 257 
microparticles with an efficiency around 95%, independently of the used solvent. However, although 258 
not very accentuated, a significant difference was observed in RFB association, which was 59% when 259 
ethanol was used versus 67% when HCl was the solvent (p < 0.05). The loading capacity was 8.2% for 260 
INH, varying within 2.6% and 2.9% for RFB, values that compare with the theoretical 8.6% for INH 261 
and 4.3% for RFB. 262 
 263 
 264 
 265 
 266 
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Table 2. Production yield (PY), median volume particle size (Dv50), tap density, drug association 267 
efficiency (AE) and loading capacity (LC) of ChS microparticles (mean ± SD, n = 3). Different letters 268 
indicate statistical significant difference within the same parameter. 269 
Microparticles PY (%) 
Dv50 
(µm) 
Span 
Tap density 
(g/cm3) 
AE% LC% 
ChS 73.3 ± 4.4a 9.6 ± 0.2c 2.0 ± 0.0e 0.50 ± 0.01g n. a. n. a. 
ChS/INH/RFB 
(ethanol) 
83.4 ± 1.0b 4.1 ± 0.1d 2.9 ± 0.1f 0.32 ± 0.03h 
INH: 94.9 ± 5.7j INH: 8.2 ± 0.5m 
RFB: 59.0 ± 6.9k RFB: 2.6 ± 0.3n 
ChS/INH/RFB 
(HCl) 
84.9 ± 1.1b 4.1 ± 0.0d 3.1 ± 0.1f 0.58 ± 0.02i 
INH: 94.6 ± 4.0j INH: 8.2 ± 0.3m 
RFB: 67.6 ± 1.4l RFB: 2.9 ± 0.1o 
AE: association efficiency, ChS: chondroitin sulfate, INH: isoniazid, LC: loading capacity, PY: production yield, 270 
RFB: rifabutin, n.a.: not applicable 271 
 272 
Figure 2 shows the stage-by-stage deposition profiles of both drugs encapsulated in the tested 273 
microparticles. The similarity of the profiles (INH vs RFB) indicates that the two drugs were equally 274 
distributed in the various stages. This suggests the adequacy of spray-drying as technique to produce 275 
microparticles with drug combination, resulting in homogeneous composition independently of 276 
particle sizes, which led to co-deposition of drugs. A statistically significant difference in the 277 
deposition of both formulations was found in the induction port, and in stages 2 and 3 (p < 0.05). This 278 
translated into differences in the calculated aerodynamic characteristics, which are displayed in Table 279 
3. The dose emitted from the inhaler was very satisfactory in all cases, reaching 90%. This is indicative 280 
of the suitability of ChS to be used as microparticle matrix material in spray-drying, producing 281 
microparticles with good flowing capacity with any of the tested solvents. Similar MMAD values (3.8 282 
– 4.0 μm) were obtained for both formulations. This aerodynamic diameter fits the range considered 283 
suitable to reach the respiratory zone, which is 1–5 µm [26, 27], thus being adequate for a tuberculosis 284 
therapy approach. Moreover, FPF of 34% - 44% was determined, indicating that this fraction of the 285 
microparticles has the aerodynamic characteristics for a deep lung deposition.  286 
 287 
 288 
Figure 2. Stage-by-stage deposition profiles of isoniazid (blue) and rifabutin (red) inside the Andersen 289 
cascade impactor after aerosolisation of chondroitin sulfate (ChS) microparticles (MPs) with RS01 290 
high resistance inhaler operated at 60 L/min (values are mean ± SD, n = 3). Grey boxes in X axis 291 
represent p < 0.05 comparing the same stage between the two formulations. IP: induction port; St: 292 
stage. 293 
 294 
Despite having very similar MMAD, microparticles produced using ethanol as solvent provided 295 
a lower deposition in the induction port and higher deposition on stages 2 and 3, in the sequence of 296 
the determined higher FPD, enabling deep lung delivery of 1.5 mg of RFB and 3.1 mg of INH. The 297 
presence of ethanol apparently benefited the formulation, resulting in a less cohesive powder with 298 
Polymers 2020, 12, x FOR PEER REVIEW 8 of 13 
 
better flowing properties. Despite the slightly lower drug association efficiency, the resulting 299 
aerodynamic properties provide increased drug accumulation in the respiratory zone comparing 300 
with that evidenced by microparticles produced with HCl.  301 
 302 
Table 3. Aerodynamic characteristics of ChS/INH/RFB (10/1/0.5, w/w) microparticles (mean ± SD, n = 303 
3). 304 
FPD: Fine particle dose; FPF: Fine particle fraction; GSD: Geometric standard deviation; MMAD: Mass median 305 
aerodynamic diameter. 306 
 307 
3.2. Impact of spray-drying on polymer characteristics 308 
Spray-drying was the technique selected to produce the microparticles, as it permits tailoring 309 
their properties for deep lung delivery. Nevertheless, it was deemed important to study the impact 310 
of the process on the polymer properties. The molecular mass distribution of ChS was investigated 311 
as raw material and after the spray-drying process (unloaded microparticles), and the obtained 312 
profiles are exhibited in the Figure 3. In both samples, the molecular mass was greater than 80 kDa, 313 
which was the highest standard available. The peaks of the two samples evidenced similar 314 
distribution profiles and, although showing a slight difference, the molecular mass was considered 315 
similar. Rani et al. (2017) isolated chondroitin sulfate from the cartilage of chicken keel bone and 316 
reported the peak of molecular mass at 100 kDa [28].  317 
 318 
 319 
Microparticles 
Powder 
Emitted dose 
(%) 
Drug 
MMAD 
(µm) 
GSD (µm) FPD (mg) FPF (%) 
ChS/INH/RFB 
(ethanol) 
90.9 ± 1.0a 
INH 3.8 ± 0.1b 1.9 ± 0.1c 3.1 ± 0.3d 43.7 ± 2.4g 
RFB 3.9 ± 0.1 b 2.0 ± 0.1c 1.5 ± 0.1e 42.6 ± 1.7g 
ChS/INH/RFB 
(HCl) 
89.6 ± 1.8a 
INH 4.0 ± 0.2 b 2.0 ± 0.0c 2.9 ± 0.1d 35.0 ± 1.7h 
RFB 4.0 ± 0.3 b 2.1 ± 0.1c 1.2 ± 0.1f 34.0 ± 3.7h 
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Figure 3. High performance size exclusion chromatography (HPSEC) profiles of chondroitin sulfate 320 
(ChS) as raw material, represented by continuous line, and after processing by spray-drying 321 
(unloaded microparticles), illustrated by dotted line. 322 
 323 
A rheological study was also performed, evaluating the rheological behaviour of the polymer 324 
before and after spray-drying and further determining the effect of associating the drugs. Figure 4 325 
displays the steady shear flow curves of the tested aqueous dispersions (10 g/L) at 25 ºC. In all cases, 326 
shear-thinning behaviour was observed, with the apparent viscosity decreasing with increasing shear 327 
rate (about 2 decades). The apparent viscosity drop can be explained by the alignment of long chain 328 
molecules with each other at the highest shear rates, leading to easier flows. This behaviour is 329 
characteristic of pseudoplastic fluids, which may be described by the power law model, and the 330 
viscosity trend is consistent with a typical non-entangled polymer behaviour in the dilute regime 331 
[29]. At a fixed shear rate, it can be clearly observed that ChS polymer exhibited the lowest apparent 332 
viscosity over the tested range. After processing by spray-drying, higher apparent viscosity values 333 
were observed (about 2-fold), suggesting an effect of the process on polymer characteristics. Since 334 
slight differences were identified in the HPSEC profiles, this behaviour suggests that some aggregates 335 
of the proper polymer chains may have formed during microparticle processing, which could involve 336 
higher flow resistance and, consequently, higher apparent viscosities. The samples corresponding to 337 
post-spray-drying products, all registered similar behaviour, indicating an absence of effect of both 338 
drug association and used solvents. Taking into account the envisaged application as inhalable 339 
tuberculosis therapy, this behaviour may help microparticles to maintain their “particulate” shape 340 
long enough to be phagocytosed prior to dissolution. It should be further highlighted that no 341 
hysteresis was observed in the tested samples, with the consequent advantage from the industrial 342 
point of view. 343 
 344 
 345 
Figure 4. Steady shear flow curves for aqueous dispersions of chondroitin sulfate (ChS) polymer, ChS 346 
unloaded microparticles and ChS/INH/RFB microparticles produced with ethanol (EtOH) or HCl, at 347 
polymer concentration of 10 g/L and 25 ºC. 348 
3.4. INH and RFB release from ChS microparticles 349 
Considering an application in tuberculosis therapy, drug release profiles were determined in 350 
PBS pH 7.4 added of 1% Tween 80®. The pH resembles that of the lung lining fluid [30] and the 351 
addition of Tween 80® intends to mimic the surfactant content [31]. The results are displayed in Figure 352 
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5 and evidence rapid release of the drugs, as 100% release was registered within 60 min for INH and 353 
120 min for RFB, in both formulations. The surface irregularities of microparticles, commented in 354 
section 3.1., certainly contributed to the rapid release, due to the increased contact with the release 355 
medium. Additionally, the high solubility of the polymeric matrix was another contributing factor, 356 
with the hydrophilic character of ChS resulting in rapid dissolution of the particle matrix and 357 
permitting a fast release of the drugs. Nevertheless, RFB tends to exhibit slower release than INH (p 358 
< 0.05). The similarity factor f2 was used to compare the release of both drugs in each formulation 359 
and also the release of each drug in the two different formulations. The comparison between INH 360 
and RFB resulted in f2 factor of 30 for microparticles produced with ethanol and 43 for microparticles 361 
produced with HCl. As f2 values are lower than 50, it is concluded that differences exist in the release 362 
profiles of both drugs in both microparticle formulations. This is possibly a consequence of the higher 363 
molecular weight of RFB, along with its hydrophobicity, which contrasts with the hydrophilic 364 
character of INH.  365 
When comparing the release of each drug from both formulations, no differences were observed 366 
for INH, as this follows a similar release pattern from both microparticles, which is reinforced by an 367 
f2 factor of 64. In contrast, Figure 5 evidences a difference in RFB release profile when the two 368 
microparticle formulations are compared. In this context, microparticles produced with ethanol 369 
provided somewhat slower release comparing with those produced with HCl (p < 0.05). A f2 factor of 370 
46 confirms the dissimilar profiles. Considering the results of the rheological study, no differences in 371 
the characteristics of the polymer were found comparing the two spray-dried microparticle 372 
formulations that could justify this behaviour. Therefore, one possible explanation for this effect 373 
could be that HCl remaining in the formulation after spray-drying facilitated RFB solubilisation 374 
afterwards, by providing a certain degree of protonation [32]. Another reason could be the existence 375 
of a different pattern of dispersion of RFB within the microparticle matrix in each formulation. If RFB 376 
is located more at the surface in microparticles produced with HCl, comparing with those produced 377 
with ethanol, this could justify the observed profiles. Nevertheless, further studies would be needed 378 
to study this possibility.  379 
 380 
Figure 5. - In vitro release of isoniazid (INH) and rifabutin (RFB) from ChS/INH/RFB (10/1/0.5, w/w) 381 
microparticles in PBS pH 7.4-Tween 80®, at 37 °C (mean ± SD, n = 3). * p < 0.05 comparing INH and 382 
RFB at a given time point. 383 
The encapsulation of the same pair of drugs was reported in other works that used different 384 
microparticle matrix materials. The comparison of release profiles supports the conclusion that the 385 
matrix rules the release pattern. Although ChS is a hydrophilic polymer, it was able to provide slower 386 
release of these drugs in comparison with microparticles composed of fucoidan, another hydrophilic 387 
polymer, which has shown total release of INH and RFB in 30 min [33]. Locust bean gum, in turn, 388 
provides more viscous solutions and, thus, sustained the release of INH until 120 min and RFB up to 389 
240 min [34], while low molecular weight chitosan microparticles released completely INH and RFB 390 
in 120 min [35]. Also chitosan, but with higher molecular weight, provided more sustained release of 391 
INH, up to 40-60 h, which was demonstrated to be influenced by the polymer properties and 392 
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crosslinking degree [36]. In fact, polymeric particles devoid of crosslinking agents typically show a 393 
faster release of the associated drugs [37]. 394 
It should be stressed that this assay does not mimic in vivo conditions, as it is well known that 395 
the alveolar epithelium is covered by a thin layer (~0.2 µm) of lung lining fluid [38]. Therefore, 396 
microparticles are expected to be only partially in contact with the fluid, and not immersed in it, as 397 
in this assay. Consequently, we anticipate that, in in vivo conditions, these microparticles will show 398 
slower drug release kinetics, allowing microparticle internalisation by macrophages before particle 399 
dissolution and complete drug release.  400 
 401 
3.5. Antibacterial activity of drugs after microencapsulation 402 
One of the most commonly administered vaccines worldwide and the only one against 403 
tuberculosis is based on M. bovis BCG, a live attenuated vaccine. BCG vaccine is commonly used in 404 
experiments as a surrogate for virulent M. tuberculosis [39]. For this reason and because BCG is a slow 405 
growing strain with similarities to M. tuberculosis, it was selected to perform this assay, determining 406 
the MIC value of INH and RFB and the effect of spray-drying on this parameter. MIC value of free 407 
and encapsulated drugs was determined by exposing M. bovis BCG during 7 days to different 408 
concentrations of free drugs, association of free INH and RFB (at INH/RFB = 2/1, to mimic the drug 409 
ratio present in the microparticles) and to the two different microparticle formulations. The MIC 410 
value observed for the free drugs was 0.125 µg/mL for INH and 0.004 µg/mL for RFB, indicating 411 
higher sensitivity of M. bovis to RFB than to INH. The literature reports variable values, in 412 
dependency of the bacterial strains and determination methods that are used, but the attained values 413 
were similar to those reported in other studies [39, 40]. When a combination of both drugs was 414 
analysed, RFB ruled the inhibition effect and the same 0.004 µg/mL concentration (0.004 RFB and 415 
0.008 INH) led to inhibition of the growth of M. bovis. Drug-loaded microparticles evidenced the same 416 
MIC value observed for the free drugs in combination, disregard of the formulation. This provides a 417 
dual indication: 1) that the spray-drying process does not affect the antitubercular effect of the drugs 418 
and 2) that the used solvent has no effect on this property of microparticles. 419 
5. Conclusions 420 
ChS microparticles were able to successfully associate a combination of INH and RFB, with 421 
efficiency between 60% and 95%, either using ethanol or HCl as co-solvent in the spray-drying 422 
process. The microencapsulation process induced some alterations in the rheological properties of 423 
the polymer, which was independent of the used solvent. In any case, the antitubercular efficacy of 424 
the drugs remained unchanged after encapsulation. Despite both the produced formulations of 425 
microparticles revealed similar aerodynamic properties and in vitro respirability, the dry powder 426 
prepared using ethanol as co-solvent showed a better ability to sustain the release of RFB. Regarding 427 
the objective of associating INH and RFB, two drugs of opposite aqueous affinity, in the same 428 
formulation of ChS microparticles aimed at lung delivery, the use of ethanol as co-solvent was 429 
considered to be advantageous. 430 
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